Authors
Latest:
Blueprint for a Great LeaderIs there a formula for the perfect biotech or pharmaceutical executive? As a candidate to be the next CEO of Pfizer or Amgen, it is better to have a PhD in microbiology or an MBA combined with a medical degree? Does a lifetime in the lab beat out a decade of sales and marketing experience?
Latest:
Pricing PressuresDuring the 2000 US election, prescription costs-especially for seniors-was a hot issue that both parties offered to resolve. Intervening events have since distracted the federal government from domestic healthcare issues, leaving states to take the initiative in lowering drug expenditures. Two states' programs led the way, drawing legal challenges from the pharmaceutical industry. Recent opinions by US courts of appeals in those cases reached conflicting results; but viewed together, they provide guidance for the types of state plans that will be sustained. Meanwhile, other programs are making their way through state legislatures around the country.
Latest:
Your new competition...It's not who you think it isDemands on physicians aren't just coming from reps.
Latest:
In Establishing the Evidence Base, He Made Science CountRobert Seidman, Former Chief Pharmacy Officer, Wellpoint
Latest:
It's All in the DetailsBrand managers assume that more information leads to more effectiveness. Unfortunately, the reverse is true.
Latest:
New Gains for PainThe global pain market will reach nearly $29.8 billion in 2008, of which $21.8 billion will come from the United States.
Latest:
The Rise and Fall of Pharma ReputationsAs a reputation driver, ethical behavior has increased steadily in importance over the last three years.
Latest:
Direct to Consumer: HIV and AdherenceThe flaw lies not in the lack of patient information, but rather in the way they process it.
Latest:
BioTech's New Business ModelCoined in the early 1940s, the hybrid term "biotech" has sustained its save-the-world aura and futurist allure. During the industry's nascent years, Amgen, Genentech, and other barrier-breaking companies were mere fledgling operations with products still in the pure science phase and their only "revenue" the hope of curing some of the world's ills.
Latest:
Also Known As...The Value of Generic NamesIn the world of pharmaceutical names, the trademark has always been the star, and every other word has played a supporting role. But recent developments at FDA-and the industry's response to those developments-have set the stage for a new approach to nomenclature.
Latest:
Key Opinion Leaders Interactions with PharmaData suggest that pharma companies engage the same key opinion leaders on assignments in three to seven departments or product groups at once.
Latest:
Pfizer Can Mold Its Future by Learning from the PastPfizer Chairman and CEO Hank McKinnell sees the company's $58 billion blockbuster acquisition of Pharmacia as the key to Pfizer's leadership in pharmaceutical markets around the globe.
Latest:
Beyond TrainingHow to Hire the Right Reps, Train Them to Excel, and Retain Them for the Long Run
Latest:
It's All in the DetailsBrand managers assume that more information leads to more effectiveness. Unfortunately, the reverse is true.
Latest:
Predicting Success: A Pipeline ReportMuch has been said about pharma's R&D lag, but a closer look at the candidates currently in Phase III shows that what the pipeline lacks in quantity it makes up for in quality. This Pharmaceutical Executive pipeline report identifies some of the top candidates in five categories: women's health, oncology, central nervous system (CNS), cardiovascular disease (CVD), and metabolic/ endocrine diseases.
Latest:
The Pivotal PrescribersThanks to managed care's efforts to steer patients into the least intensive treatment settings, primary care practitioners (PCPs) play an increasingly important role in prescribing.
Latest:
Generics Battle Heats UpThe competition for generics' 180-day marketing exclusivity is fierce, and Dr. Reddy's Laboratories filed the first court case calling into question FDA's methods for determining exclusivity on a patent-by-patent basis.
Latest:
PE's annual Media Spend TrendsThe economy may still be suffering from the twin shocks of September 11th and a bursting technology bubble, but pharma spending on promotions continues to grow at a double-digit pace.
Latest:
Understanding physician stress (Part Two)Understanding physician stressors and the behavior that follows is one key to enhancing relationships.
Latest:
Canaries in the Coal MineMSL programs were a technical outgrowth of sales, but they have since evolved to partake in field-based clinical and educational efforts for companies’ products. However, in many pharma companies, that evolution has not gone far enough. Companies still continue to focus MSL activities on pushing information out rather than pulling it in from the field and integrating it into their decision-making processes. As such, companies are missing the opportunity to leverage MSLs within a sensory web.
Latest:
Pharma WANTS YOUWhen it comes to recruiting and enrolling individuals in clinical trials, the industry's challenge is similar to the one that General Riggs cites in his call to modernize the US Army.
Latest:
A Better Way to Manage the PipelineA major unresolved issue for the pharmaceutical industry in the 21st century is that few, if any, optimization techniques have found their way into the research portfolio arena.
Latest:
Surviving Career TransitionsPharma is finally feeling the ill effects of the US economic downturn. In response, many companies are restructuring and downsizing. But pharma industry professionals are well positioned to take advantage of many avenues of employment, including other industries, entrepreneurial ventures, and consulting.
